FINWIRES · TerminalLIVE
FINWIRES

XRF Scientific Fiscal Q3 Results Broadly in Line With Expectations, Euroz Hartleys Says

-- XRF Scientific (ASX:XRF) delivered a fiscal third-quarter trading update broadly in line with expectations, supporting unchanged full-year estimates, driven by strength in consumables and momentum in capital equipment, Euroz Hartleys said in a Wednesday note.

The company reported that pre-tax profit for the March quarter rose nearly 11% to AU$3.7 million from AU$3.4 million a year earlier, while revenue increased 14% to AU$15.8 million from AU$13.9 million.

The firm noted that consumables drove the quarter, with revenue of AU$4.8 million supported by strong Asian demand, record March volumes, and a healthy AU$1 million order book expected to roll into the fourth quarter due to near-immediate fulfilment.

The firm highlighted that capital equipment revenue rose 20% year-on-year to AU$5.4 million, driven by strong Orbis crusher activity contributing AU$2.5 million, with gold sector demand supporting continued momentum into the next quarter.

The firm stated that precious metals sales rose 14% year-on-year to AU$5.6 million, helped by stronger period-end demand as platinum prices eased, with softer pricing supporting new product sales.

The firm remained positive on the stock, citing sustained growth prospects supported by rising production, stronger international demand, a solid equipment pipeline, and potential accretive acquisitions.

Euroz Hartleys maintained its buy recommendation and AU$2.21 price target on XRF Scientific.

相關文章

Research

研究報告:CFRA維持對德州儀器公司股票的「持有」評級

獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:我們將12個月目標價從224美元上調至273美元,基於2027年每股收益的30倍市盈率,高於同行以及德州儀器五年歷史平均市盈率(約27倍),這反映了我們對公司基本面改善和自由現金流潛力的預期。在第一季業績強勁超出預期後,我們將2026年每股收益預期從6.76美元上調至7.87美元,並將2027年每股收益預期從7.73美元上調至9.10美元。第一季工業業務收入成長超過30%(季增20%),更廣泛的工業市場(數千家小型客戶)在經歷了長期的低迷後重新活躍起來。儘管如此,工業業務收入仍比2022年第三季的峰值低15%,這意味著公司至少還有4-6個季度的成長空間。多年來高企的資本支出如今使德州電力公司(TXN)能夠滿足客戶需求,不再出現供應短缺,並憑藉更充足的供應能力重新奪回市場份額。資本支出放緩的效應也開始顯現,我們預計到2027年,自由現金流將遠超80億美元(2025年為26億美元),同時,隨著產能利用率的提高和定價表現好於預期,毛利率也將出現好轉。

$TXN
Asia

東洋人壽保險將註銷價值467億韓元的庫存股

根據東洋生命保險(KRX:082640)週五向韓國交易所提交的文件,該公司計劃回購約530萬股庫存股,價值467億韓元。 這些股票將於4月30日以每股5000韓元的面額回購。 東洋生命保險的股價在收盤時上漲超過1%。

$KRX:082640
Asia

華東醫藥第一季歸屬於股東的淨利成長9.6%;股價上漲3%。

華東醫藥(深圳證券交易所代碼:000963)週五向深圳證券交易所提交的公告顯示,該公司第一季歸屬於股東的淨利潤年增9.6%,達到10億元人民幣,而去年同期為9.147億元人民幣。 該公司每股收益從去年同期的0.5213元增加到0.5715元。 營業利潤年增4.2%,從107億元增至112億元。 週五午後交易時段,該公司股價上漲3%。

$SHE:000963